A 33-year-old male is experiencing thinning at the temples and hairline, with increased shedding over the past year. The user suspects androgenetic alopecia (AGA) despite AI suggesting a maturing hairline.
A user shared their 12-month update after a 5,800-graft hair and beard transplant performed by Dr. Tulunay in Istanbul, using Sapphire FUE and DHI techniques. The user noted significant growth around months 8-9 and expressed satisfaction with the results.
The individual had a hair transplant in Turkey with 4052 grafts, resulting in significant hair growth and increased confidence. They use finasteride, rosemary oil, and vitamins, and are pleased with the natural-looking results, encouraging others to consider similar treatments.
The conversation is about using GHK-Cu, a copper peptide, for hair loss treatment. Users discuss their experiences, dosages, and additional benefits like improved skin and energy.
A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.
GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.
GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.
The user shared their positive experience with a hair transplant in South Korea, highlighting thorough consultations, consistent medical team involvement, and reasonable pricing. They noted good growth and natural-looking results after several months, with stem cell PRP treatment included to support graft survival.
The conversation discusses using gartanin from mangosteen mixed with castor oil to degrade the androgen receptor for hair loss treatment. Alternatives like setipiprant, minoxidil, and dermastamping are also mentioned, with concerns about cost and potential side effects.
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
A 35-year-old man shared his hair transplant experience in Tijuana, Mexico, choosing Artline for 5,000 grafts at a lower cost than U.S. clinics. He plans to use topical minoxidil and possibly microneedling for better results.
A user is seeking recommendations for top hair transplant surgeons outside the US, focusing on hairline work and density, with a budget of $3,000 to $8,000. They prefer locations closer than Turkey due to travel constraints.
Finasteride can cause gynecomastia, which may be reversible by stopping the drug and using selective estrogen receptor modulators (SERMs) like tamoxifen. Lifestyle changes such as weight loss and avoiding alcohol can also help, but surgery may be needed if the condition persists.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
Deoxyribose sugar gel is discussed as a potential hair loss treatment, but it lacks human trials and credible evidence. Users express skepticism and humor about its effectiveness compared to established treatments like minoxidil and finasteride.
A user shared positive 6-month results from a hair transplant in Istanbul, receiving 4,450 grafts for the front and mid scalp and 850 for the crown. The procedure cost approximately €2,990.
The conversation is about comparing keratin hair fibers to Gossypium Herbaceum hair fibers for diffuse hair loss. The user prefers keratin fibers for their durability and is seeking a bulk purchase option.
A user shared their positive experience with a 4200-graft hair transplant performed by Dr. Heena Kudyar, noting significant improvement in hairline and density by month 9. The user did not mention using medications like Minoxidil, Finasteride, or RU58841.
A user shared their positive experience with a 4750 graft hair transplant at Dr. Orçun Clinic in Istanbul, including a high-quality exosome treatment. Despite skepticism and accusations of advertising, the user expressed satisfaction with the natural-looking results and the doctor's personal involvement.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
GHK-Cu is being discussed as a potential treatment for male pattern baldness. Users are sharing experiences and asking about its effectiveness and side effects.
The user is considering a hair transplant in Greece, where the doctor uses a pen technique for natural results and charges a fair price. They are seeking opinions on the doctor's work before proceeding.
The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.
The conversation discusses the availability of GT20029, a new topical hair loss treatment with fewer side effects than Minoxidil or finasteride. Users suggest using finasteride to preserve hair until GT20029 becomes available.
The post discusses using ImageJ software to objectively track hair regrowth progress. The user is treating Androgen alopecia with dutasteride and minoxidil.
Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.